Repligen (RGEN) Cash from Financing Activities (2010 - 2026)
Repligen's (RGEN) quarterly Cash from Financing Activities came in at -$6.2 million in Q2 2026, up 38.8% year-over-year from -$4.5 million in Q2 2025, and down 11.85% quarter-over-quarter from -$5.5 million in Q1 2026.
Analysis
Repligen (RGEN) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Repligen (RGEN) has reported Cash from Financing Activities for 17 consecutive years, with -$6.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Financing Activities rose 38.8% year-over-year to -$6.2 million in Q2 2026; TTM through Jun 2026 was -$11.8 million, a 85.85% increase from a year earlier, with the FY2025 full-year figure at -$15.2 million, up 81.66% from the prior year.
- Cash from Financing Activities was -$6.2 million for Q2 2026 at Repligen, down from -$5.5 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $268.1 million in Q4 2023 and troughed at -$69.6 million in Q3 2024.
- A 5-year average of $7.0 million and a median of -$5.3 million in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities jumped 97956.57% in 2023 and tumbled 8846.53% in 2024, its largest moves.
- Over 5 years, Cash from Financing Activities stood at -$274000.0 in 2022, then jumped by 97956.57% to $268.1 million in 2023, then plunged by 99.46% to $1.4 million in 2024, then slumped by 86.54% to $195000.0 in 2025, then plunged by 3279.49% to -$6.2 million in 2026.
- The last three Cash from Financing Activities figures came in at -$6.2 million (Q2 2026), -$5.5 million (Q1 2026), and $195000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | -1.57 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | 7.27 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | 471.00 Mn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | -129.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | -23.16 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | -33.21 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | -27.60 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | -6.20 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | 3.02 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | 149.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6.20 Mn |
| Mar 31, 2026 | -5.54 Mn |
| Dec 31, 2025 | 195,000.00 |
| Sep 30, 2025 | -239,000.00 |
| Jun 30, 2025 | -10.13 Mn |
| Mar 31, 2025 | -5.03 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | -69.60 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -8.97 Mn |
| Dec 31, 2023 | 268.13 Mn |
| Sep 30, 2023 | -778,000.00 |
| Jun 30, 2023 | -8.83 Mn |
| Mar 31, 2023 | -9.56 Mn |
| Dec 31, 2022 | -274,000.00 |
| Sep 30, 2022 | 1.25 Mn |
| Jun 30, 2022 | -2.29 Mn |
| Mar 31, 2022 | -12.02 Mn |
| Dec 31, 2021 | 231,000.00 |
| Sep 30, 2021 | -122,000.00 |